CN116745300A - 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物 - Google Patents
作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物 Download PDFInfo
- Publication number
- CN116745300A CN116745300A CN202180076849.5A CN202180076849A CN116745300A CN 116745300 A CN116745300 A CN 116745300A CN 202180076849 A CN202180076849 A CN 202180076849A CN 116745300 A CN116745300 A CN 116745300A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- group
- optionally
- optionally substituted
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311341729.0A CN117624188A (zh) | 2020-11-16 | 2021-11-12 | 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207719 | 2020-11-16 | ||
| EP20207719.4 | 2020-11-16 | ||
| PCT/EP2021/081459 WO2022101377A1 (en) | 2020-11-16 | 2021-11-12 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311341729.0A Division CN117624188A (zh) | 2020-11-16 | 2021-11-12 | 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116745300A true CN116745300A (zh) | 2023-09-12 |
Family
ID=73543025
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180076849.5A Pending CN116745300A (zh) | 2020-11-16 | 2021-11-12 | 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物 |
| CN202311341729.0A Pending CN117624188A (zh) | 2020-11-16 | 2021-11-12 | 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311341729.0A Pending CN117624188A (zh) | 2020-11-16 | 2021-11-12 | 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11766443B2 (https=) |
| EP (1) | EP4244229A1 (https=) |
| JP (2) | JP7465368B2 (https=) |
| KR (1) | KR20230109692A (https=) |
| CN (2) | CN116745300A (https=) |
| AR (1) | AR124070A1 (https=) |
| AU (1) | AU2021379248A1 (https=) |
| CA (1) | CA3200710A1 (https=) |
| CL (2) | CL2023001361A1 (https=) |
| CO (1) | CO2023005894A2 (https=) |
| CR (1) | CR20230211A (https=) |
| DO (1) | DOP2023000090A (https=) |
| EC (1) | ECSP23036210A (https=) |
| IL (1) | IL302769A (https=) |
| JO (1) | JOP20230107A1 (https=) |
| MX (1) | MX2023005678A (https=) |
| PE (1) | PE20231855A1 (https=) |
| SA (1) | SA523440809B1 (https=) |
| WO (1) | WO2022101377A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119842821A (zh) * | 2025-01-06 | 2025-04-18 | 华中科技大学 | 稳定表达血小板活化因子受体的细胞株、构建方法及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3502392A1 (de) | 1985-01-25 | 1986-07-31 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen |
| IE870123L (en) * | 1986-01-21 | 1987-07-21 | Boehringer Ingelheim Int | Thieno-1,4-diazepines |
| PH30676A (en) | 1986-07-22 | 1997-09-16 | Boehringer Ingelhein Kg | Hetrazepine compounds which have useful pharmaceutical utility |
| US4959361A (en) * | 1987-12-18 | 1990-09-25 | Hoffmann-La Roche Inc. | Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists |
| MC1999A1 (fr) * | 1987-12-18 | 1990-01-26 | Hoffmann La Roche | Composes tricycliques |
| DE3909012A1 (de) | 1989-03-18 | 1990-09-20 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen |
| DE4010528A1 (de) | 1990-04-02 | 1991-10-17 | Boehringer Ingelheim Kg | Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine |
| DE4132763A1 (de) | 1991-10-02 | 1993-04-08 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur |
| FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| US20050032713A1 (en) * | 2002-03-27 | 2005-02-10 | Wurtman Richard J. | Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents |
| CA2670031A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
-
2021
- 2021-11-12 PE PE2023001605A patent/PE20231855A1/es unknown
- 2021-11-12 IL IL302769A patent/IL302769A/en unknown
- 2021-11-12 MX MX2023005678A patent/MX2023005678A/es unknown
- 2021-11-12 CN CN202180076849.5A patent/CN116745300A/zh active Pending
- 2021-11-12 AU AU2021379248A patent/AU2021379248A1/en active Pending
- 2021-11-12 CR CR20230211A patent/CR20230211A/es unknown
- 2021-11-12 EP EP21806745.2A patent/EP4244229A1/en active Pending
- 2021-11-12 KR KR1020237020295A patent/KR20230109692A/ko active Pending
- 2021-11-12 JP JP2022562298A patent/JP7465368B2/ja active Active
- 2021-11-12 CN CN202311341729.0A patent/CN117624188A/zh active Pending
- 2021-11-12 CA CA3200710A patent/CA3200710A1/en active Pending
- 2021-11-12 US US17/524,759 patent/US11766443B2/en active Active
- 2021-11-12 WO PCT/EP2021/081459 patent/WO2022101377A1/en not_active Ceased
- 2021-11-15 AR ARP210103159A patent/AR124070A1/es unknown
-
2023
- 2023-05-08 CO CONC2023/0005894A patent/CO2023005894A2/es unknown
- 2023-05-11 CL CL2023001361A patent/CL2023001361A1/es unknown
- 2023-05-11 DO DO2023000090A patent/DOP2023000090A/es unknown
- 2023-05-16 SA SA523440809A patent/SA523440809B1/ar unknown
- 2023-05-16 JO JOJO/P/2023/0107A patent/JOP20230107A1/ar unknown
- 2023-05-17 EC ECSENADI202336210A patent/ECSP23036210A/es unknown
- 2023-07-14 US US18/221,936 patent/US20230355638A1/en active Pending
-
2024
- 2024-02-01 CL CL2024000317A patent/CL2024000317A1/es unknown
- 2024-03-29 JP JP2024055696A patent/JP7810743B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN117624188A (zh) | 2024-03-01 |
| CR20230211A (es) | 2023-07-13 |
| US20220160725A1 (en) | 2022-05-26 |
| WO2022101377A1 (en) | 2022-05-19 |
| US20230355638A1 (en) | 2023-11-09 |
| CO2023005894A2 (es) | 2023-05-29 |
| ECSP23036210A (es) | 2023-06-30 |
| AR124070A1 (es) | 2023-02-08 |
| JP2024099528A (ja) | 2024-07-25 |
| KR20230109692A (ko) | 2023-07-20 |
| TW202237620A (zh) | 2022-10-01 |
| JP7465368B2 (ja) | 2024-04-10 |
| MX2023005678A (es) | 2023-05-26 |
| US11766443B2 (en) | 2023-09-26 |
| JP7810743B2 (ja) | 2026-02-03 |
| CA3200710A1 (en) | 2022-05-19 |
| AU2021379248A9 (en) | 2024-10-10 |
| CL2024000317A1 (es) | 2024-07-12 |
| DOP2023000090A (es) | 2023-06-15 |
| JOP20230107A1 (ar) | 2023-05-16 |
| AU2021379248A1 (en) | 2023-06-22 |
| IL302769A (en) | 2023-07-01 |
| CL2023001361A1 (es) | 2023-11-03 |
| SA523440809B1 (ar) | 2024-10-08 |
| JP2023521200A (ja) | 2023-05-23 |
| PE20231855A1 (es) | 2023-11-21 |
| EP4244229A1 (en) | 2023-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112041302B (zh) | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 | |
| JP7299892B2 (ja) | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン | |
| TW201927765A (zh) | 作為lpa拮抗劑之三唑n-連接之胺甲醯基環己基酸 | |
| CN113039181B (zh) | 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物 | |
| JP2021507898A (ja) | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール | |
| CN112702998A (zh) | 作为lpa拮抗剂的环庚酸 | |
| JP2025500886A (ja) | 大環状ｂｔｋ阻害剤 | |
| WO2014101295A2 (zh) | 一种詹纳斯激酶（JAKs）抑制活性的异恶唑衍生物 | |
| JP7703587B2 (ja) | 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体 | |
| EP1301516A1 (en) | Modulators of protein tyrosine phosphatases (ptpases) | |
| JP7810743B2 (ja) | 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体 | |
| WO2002004458A1 (en) | Modulators of protein tyrosine phosphatases (ptpases) | |
| TWI913356B (zh) | 作為血小板活化因子受體拮抗劑之環戊烷并噻吩甲醯胺衍生物 | |
| CN112839711A (zh) | 作为血浆激肽释放酶抑制剂的苯基四唑衍生物 | |
| EA048242B1 (ru) | Циклопентатиофенкарбоксамидные производные в качестве антагонистов рецептора фактора активации тромбоцитов | |
| JP2025501761A (ja) | 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体 | |
| US20020099073A1 (en) | Modulators of protein tyrosine phosphatases (PTPases) | |
| CN121085992A (zh) | 信号转导及转录激活蛋白6选择性降解剂化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |